Inflammatory Bowel Disease Treatment Market Size to Surpass USD 40.8 BN by 2030

The global Inflammatory Bowel Disease Treatment market size was estimated at USD 25.20 billion in 2022 and is expected to surpass around USD 40.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.1% during the forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6912

Key Takeaways:

• By Drug Class, the U.K. Inflammatory Bowel Disease Treatment market was valued at USD 1.0 Billion in 2021 and expected to witness growth at a CAGR of 5.80% from 2022 to 2030.
• In 2021, Crohn’s disease accounted for the largest revenue share of more than 60.0% and is anticipated to maintain its dominance over the forecast period
• Based on drug class, the TNF inhibitors segment dominated the market in 2021 owing to the high prescription rate of Humira and Remicade globally
• Pipeline candidates in the JAK inhibitors drug class such as upadacitinib, tofacitinib, and filgotinib are anticipated to drive the segment growth at the fastest rate from 2021 to 2028
• The oral drugs segment is anticipated to grow at the fastest rate over the forecast period owing to an increase in approval of pipeline drugs such as upadacitinib, etrasimod, ozanimod, and others
• Asia Pacific is expected to witness the fastest growth in the coming years owing to rising approval of biosimilars and increasing awareness related to the disease
• North America held the largest market owing to the adoption of biologics for IBD treatment and better reimbursement scenarios in the country

The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive market growth over the forecast period. Moreover, increasing adoption of biologics for the treatment and the presence of strong pipeline drugs such as upadacitinib, risankizumab, tofacitinib, ustekinumab, and others is anticipated to boost the market growth in the coming years. The impact of the COVID-19 pandemic on the market was negligible in 2020 whereas, a downfall in the diagnosis of inflammatory bowel disease has been observed in many countries due to the complete lockdown imposed in those countries.

Increasing awareness about the disease, rise in geriatric population, and favorable initiatives undertaken by regulatory bodies are anticipated to drive the market growth over the forecast period. For instance, in January 2020, the U.S. FDA allowed ABIVAX to conduct a phase 2B clinical trial of ABX464 on U.S. patients living with moderate-to-severe ulcerative colitis.

Increasing adoption of strategies such as new product development and expansion is expected to drive market growth. For instance, in June 2020, Takeda Pharmaceutical received U.S. FDA approval to manufacture Entyvio (vedolizumab) in its U.S.-based manufacturing facility. The approval is expected to support the growing demand for the drug in the U.S. and nearby countries. Moreover, Takeda pharmaceutical is heavily investing in the development of the market in China.

An increase in initiatives undertaken by various organizations to tackle the challenges in the development of novel therapy development is expected to boost the market growth in the coming years. For instance, in May 2019, Crohn’s and Colitis Foundation released a five-year plan to mark unmet needs in IBD research and development and IBD treatment. Moreover, European Chronic Disease Alliance has taken many steps to improve the life of patients living with inflammatory bowel disease.

Implementation of favorable healthcare policies in developed countries is increasing the prescription of novel drugs for the treatment of inflammatory bowel disease. For instance, in September 2017, the Australian Therapeutic Goods Administration listed Stelara on Pharmaceutical Benefits Scheme (PBS) for the treatment of the severe condition of Crohn’s disease in adults. PBS listing of Stelara will increase the prescription of the drug in the country.

The clinical-stage companies involved in the development of innovative treatments for IBD are expected to fuel the market growth. For instance, Germany-based Sterna Biologicals, a clinical-stage company is conducting phase IIb clinical trials for the treatment of ulcerative colitis. Moreover, Galapagos NV, a research-based company is conducting phase 3 clinical trials for its JAK inhibitor, Filgotinib, for the treatment of Crohn’s disease and ulcerative colitis. The product is expected to receive approval for IBD treatment in the next 2 to 3 years.

Regulatory bodies are encouraging the manufacturers to increase research initiatives by introducing programs such as U.S. Orphan Drug Program. For instance, in August 2017, InDex Pharmaceuticals Holding AB’s drug candidate cobitolimod (intended for the treatment of ulcerative colitis) received orphan drug designation by the U.S. FDA. In August 2019, the drug met the primary endpoints of phase 2b clinical studies for the development of ulcerative colitis treatment.

Report Scope of the Inflammatory Bowel Disease Treatment Market

Type Insights

Crohn’s disease dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 61.3% in 2020. The segment is anticipated to maintain its dominance throughout the forecast period. High prevalence rate, increasing prescription rate of biologics, and high cost associated with Crohn’s disease treatment are factors driving the market for inflammatory bowel disease treatment. According to Crohn’s and Colitis Foundation, around 25% of patients with Crohn’s disease in the U.S. are prescribed biologics. Moreover, the prevalence of Crohn’s disease in North America and Europe is about 319 per 100,000 population and 322 per 100,000 population respectively.

The ulcerative colitis segment is anticipated to witness significant growth over the forecast period due to the high patient base and increasing approval of biologics for the treatment of ulcerative colitis. Ulcerative colitis patients accounted for 54% of the total diagnosed inflammatory bowel disease patients in the U.S. and Europe in 2020. Moreover, the usage of biologics to treat ulcerative colitis is anticipated to increase at a significant rate in the coming years.

Drug Class Insights

The TNF inhibitors segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 47.8% in 2020. The segment is anticipated to maintain its dominance during the forecast period. The high prescription rate of TNF inhibitors such as Humira & Remicade and the effectiveness of drugs on IBD are anticipated to increase its demand over the forecast period. However, the loss of market exclusivity of Humira in the United States in 2023 is expected to negatively impact the growth of the segment in the country. In 2023, biosimilars for Humira such as Hyrimoz, Imraldi, Hadlima, and others are expected to be launched in the United States. The introduction of biosimilars is anticipated to decrease the market share of TNF inhibitors in terms of revenue.

The drug classes such as anti-integrin, aminosalicylates, and corticosteroids also have a significant share in the inflammatory bowel disease treatment market. Aminosalicylates is the first-line therapy for IBD treatment. However, JAK inhibitors are expected to grow at the fastest rate over the forecast period. The recent approval of Pfizer’s Xeljanz for the treatment of ulcerative colitis and the presence of late-phase pipeline candidates such as upadacitinib, tofacitinib, and filgotinib are expected to drive the JAK inhibitors segment growth over the forecast period.

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/6912

Route of Administration Insights

The injectable segment dominated the market for inflammatory bowel disease treatment and accounted for a revenue share of more than 75.0% in 2020. The dominance of the injectable segment is owing to the high efficacy of the injectable drugs. Injectables include IL inhibitors such as Stelara (ustekinumab), TNF inhibitors such as Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab), and anti-integrin Tysabri (natalizumab), Entyvio (vedolizumab). The high prescription rate and the high cost of these drugs are major factors for the dominance of the injectables segment.

The oral route of drug administration is estimated to witness the highest growth rate over the forecast period. The growth of this segment can be attributed to the approval of JAK inhibitors for IBD treatment and the presence of strong oral pipeline products for the treatment of inflammatory bowel disease. The impending launch of JAK inhibitors and S1P modulators is expected to boost the market growth in the coming years.

Distribution Channel Insights

The hospital pharmacy segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 46.8% in 2020. The segment is anticipated to dominate the market over the forecast period. The high cost of biologics and increase in hospitalization of inflammatory bowel disease patients is driving the market growth. Retail pharmacy held the second-largest share in the IBD market and is expected to increase at a lucrative growth rate over the forecast period.

The online pharmacy segment is expected to grow at the fastest rate in the next 6 to 8 years. The growth of the online pharmacy segment can be attributed to the increase in online consultations from specialist doctors and the convenience and flexibility in online medicine purchasing. Moreover, the overall increase in internet usage and betterment in rules and regulations related to online purchasing of medicinal products are fueling the market growth.

Regional Insights

North America dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of around 60.0% in 2020. The region is expected to experience lucrative growth over the forecast period. High treatment rates, increasing prescription of novel drugs, and better reimbursement policies in the region are factors supporting market growth in the region. Moreover, increasing research and development activities to develop effective treatment options and the presence of major pharmaceutical companies in the region are the factors expected to fuel market growth over the forecast period. For instance, according to the U.S. National Library of Medicine, as of October 2019, there is a total of 730 clinical trials related to IBD, and out of these, 268 clinical trials are being conducted in the United States only.

In Asia Pacific, the market for inflammatory bowel disease treatment is anticipated to grow at the fastest rate over the forecast period. The increasing prevalence of Crohn’s disease and ulcerative colitis in the region, increasing prescription of biosimilars, and rising novel drug approval are expected to drive the market in the coming years. According to a study published in NCBI, the prevalence of Crohn’s disease is higher in men compared to women. The highest incidence of inflammatory bowel disease is observed in East Asia including Japan, Korea, China, and others. Moreover, economic growth in the countries such as India and China is expected to propel market growth.

Some of the prominent players in the Inflammatory Bowel Disease Treatment Market include:

• AbbVie Inc.
• Biogen
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• UCB S.A.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Pfizer Inc.
• Lilly

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Inflammatory Bowel Disease Treatment market

• Type
  • Crohn’s Disease
  • Ulcerative Colitis
• Drug Class
  • Aminosalicylates
  • Corticosteroids
  • TNF inhibitors
  • IL inhibitors
  • Anti-integrin
  • JAK inhibitors
  • Others
• Route of Administration
  • Oral
  • Injectable
• Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6912

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/